Biotech | May 01, 2022
Inmagene receives USFDA's IND clearance for ox40 antagonist
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
The procedure, named 'Shetty Test' after its creator, could change the way suspected fractures are treated
In addition, common light chain antibodies generated by RenLite mice can greatly improve the efficiency of downstream assembly of complex drug molecules such as bispecific antibodies and bispecific antibody-drug conjugates (bsADCs)
Strive to empower public health with disinfection robotics solutions in post-pandemic era
Approval for primary and booster immunization is based on efficacy and safety data from Japan and international clinical studies
A comprehensive assessment of the organisational systems for governance, management, operations and consistency in delivered results, this certification is an endorsement of the company's export capabilities and manufacturing prowess
Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults
Clinical improvements were consistent across patient subgroups including age, gender, ethnicity, and IL-36 gene mutation status
This announcement comes after the formation of a new Intercontinental Region within GE Healthcare, led by Chaillot
Milltrust Ventures will also assist Oncoshot with its expansion in Australia and India, where the latter has already established partnerships amongst apex cancer institutes
Subscribe To Our Newsletter & Stay Updated
